Radioactive 'Smart Bomb' targets tough childhood cancer
NCT ID NCT01163383
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This expanded access program provides 131 I-MIBG therapy for children and young adults with refractory or relapsed neuroblastoma, a cancer that hasn't responded to standard treatments. The therapy uses a radioactive compound that is taken up by cancer cells, delivering radiation directly to kill them. Patients receive intravenous doses every 4-8 weeks, and the program also collects data on how well it works and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 131 I-Metaiodobenzylguanidine (131 I-MIBG)
- What this could lead to
- If successful, this therapy could offer a treatment option for children with neuroblastoma that hasn't responded to standard treatments, potentially shrinking tumors and improving outcomes.
- What could go wrong
- This is an expanded access protocol, not a formal trial, so data is limited. Response rates vary, and there are risks from radiation exposure, including potential damage to healthy tissues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDHOOD METASTATIC PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Children's Hospital of Philadelphia
AVAILABLEPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a shorter chemo combo tame High-Risk neuroblastoma?
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
- Can AI read tumor slides to outsmart childhood cancer?
- Can a radioated molecule shrink untreatable neuroblastoma?
- New drug aims to shrink rare adrenal tumors